Fig. 3: Exploratory biomarker analyses.

a The top-ranked mutated genes in the studied cohort with colors representing different types of mutations (n = 26). b Kaplan–Meier survival curves depicting the PFS of patients carrying any of the BRAC2, BRINP2, FBXW7, KIT, RB1 mutations or wild type. c The best response of patients with ctDNA clearance at C1 or C2 and those without ctDNA clearance including baseline clearance patients. d The best response of patients with ctDNA clearance at C1 or C2 and those without ctDNA clearance, excluding baseline clearance patients. e Kaplan–Meier survival curves depicting the PFS times of patients with ctDNA clearance or with ctDNA uncleared at C2 including baseline clearance patients. f Kaplan–Meier survival curves depicting the PFS times of patients with or without ctDNA clearance at C2 excluding baseline clearance patients. g Correlation between ctDNA dynamics and the clinical response. b, e, f p values were calculated using the one-sided log-rank test at a significance level of 0.05. c–d Two-sided Fisher’s exact test. BRCA2 breast cancer gene 2, BRINP3 BMP/Retinoic Acid Inducible Neural Specific 3, CI confidence interval, ctDNA circulating tumor DNA, FBXW7 F-box/WD repeat-containing protein 7, HR hazard ratio, KIT tyrosine-protein kinase KIT, Mut mutation, PFS progression-free survival, RB1 retinoblastoma 1, Wt wild type. Source data are provided in the Source Data file.